Catabasis Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jill Milne
- Full Time Employees
- 20
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 High Street, 28th Floor Boston MA United States of America 02139
- IPO Date
- Jun 25, 2015
- CIK
- 0001454789
- Website
- catabasis.com
- Similar Companies
- Business
- Catabasis Pharmaceuticals, Inc. (CATB) develops novel small molecule therapeutics targeting lipid metabolism disorders and rare diseases. The company focuses on proprietary TORPEDO platform technology to create liver-targeted therapies, including edasalonexent (CAT-1004), a NF-κB inhibitor for Duchenne muscular dystrophy; CAT-5571, an apoC-III inhibitor for familial chylomicronemia syndrome; and CAT-2060 for cardiovascular indications; as well as preclinical programs in complement-mediated diseases. Operations are primarily in the United States, with headquarters in Waltham, Massachusetts, where the company was founded in 2005 as a clinical-stage biotechnology firm targeting unmet needs in metabolic and inflammatory conditions. In recent developments within the last two years, Catabasis has undergone significant strategic shifts, including the discontinuation of its Duchenne muscular dystrophy program following Phase 3 trial results in 2021 and a pivot toward rare disease opportunities, alongside potential delisting from Nasdaq due to low market capitalization and exploration of strategic alternatives such as mergers or acquisitions. No major partnerships, funding rounds, or new product launches have been publicly announced since 2023, reflecting a period of operational streamlining in the competitive biotech sector.
Catabasis Renames As Astria Therapeutics With New Disease Focus
Catabasis Pharmaceuticals Shares: 1-For-6 Split Goes Into Effect
Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition
CATB Stock Price Increases Over 40% Pre-Market: Why It Happened
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know
Catabasis Pharmaceuticals News: Why CATB Stock Is Plummeting 69% Today
SAB Biotherapeutics annonce le dosage du premier patient de l’essai clinique de phase 1b de SAB-185 pour le traitement du COVID-19
Dentistry – your ticket around the globe? Part three – Dentistry Online
SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19
Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
Questions; Confusion Regarding Military Medical System
SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program
Study: Benefits of Omega-3 on Alzheimer's Patients Reliant on Dose | WholeFoods Magazine